India’s Glenmark Continues Push Into European Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian drug maker Glenmark Pharmaceuticals will launch a division in Poland by acquiring seven generic pharmaceutical brands from Actavis, the Iceland-based generics major, and its Polish affiliate Biovena. The buy provides Glenmark an entry into the Polish market, estimated to be the largest in Central and East Europe
You may also be interested in...
India’s Glenmark Establishes Unit In Romania
India's Glenmark Pharmaceuticals has established a new unit in Romania to produce specialty drugs. Glenmark sees a $50 million market in Romania within the next five years. Romania recently was admitted into the European Union and becomes the third European country to see a Glenmark unit established. (Click here for more
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).